Stratus Medical - Radiofrequency Ablation Innovation Leader

admin52026-04-17 10:10:14

📢 Important Milestones (2026):
In March 2026, Stratus Medical was named to Fortune's America's Most Innovative Companies 2026, ranking 45th out of 300 companies evaluated. In February 2026, the company completed a $10 million Series B financing led by Wasatch Health Partners to advance development of its neurovasis™ BVNA system and proprietary RF generator.

Company Overview (Updated April 2026)

Stratus Medical is a privately held medical device company headquartered in Magnolia, Texas. Founded in 2019, the company is dedicated to reducing pain and improving the quality of life for chronic pain patients through innovative radiofrequency ablation technologies. The company has Rapidly gained market share in the United States and international markets.

Mission: To improve clinical outcomes for chronic pain patients by advancing radiofrequency technology for the treatment of pain, delivering innovative devices that provide sustained pain relief with faster procedure times and lower costs.

Financial and Innovation Highlights (2026)

Series B Financing (February 4, 2026)

Financing Details:

- Amount Raised: $10 million in Series B financing

- Lead Investor: Wasatch Health Partners (Salt Lake City-based healthcare investment firm)

- Total Funding: Approximately $42.7 million raised to date

- Use of Funds: Complete development of the Stratus® RF generator and neurovasis™ basivertebral nerve ablation (BVNA) technology, expand patent portfolio, and fund clinical studies

Fortune's America's Most Innovative Companies 2026 (March 25, 2026)

- Ranking: 45th out of 300 companies recognized

- Evaluation Criteria: Product innovation, process innovation, and innovation culture assessed by Fortune and Statista

- Other Recognized Medical Device Companies: Boston Scientific, Zimmer, Stryker

- Company Innovation Investment: 40% of cumulative revenue invested into product development since 2020

Other Recognitions

- Deloitte Technology Fast 500: Recognized for revenue growth

- Pepperdine Most Fundable Companies: Recognized for funding potential

- Houston Business Journal Top 300 Private Companies: Ranked among fastest-growing companies

Core Products and Technology Pipeline

NIMBUS® RF Multitined Expandable Electrode

The NIMBUS® is a patented multitined expandable radiofrequency electrode designed for chronic pain treatment:

- Design: Minimally invasive multitined expandable electrode creating an optimally shaped large volume lesion

- Clinical Benefits: Faster procedure times, lower costs, predictable and durable pain relief

- Market Adoption: Rapidly gained market share in the US and international markets based on ease of use and clinical efficacy

neurovasis™ Basivertebral Nerve Ablation (BVNA) System

- Target Condition: Vertebrogenic low back pain (vertebral endplate damage)

- Technology: Builds on the NIMBUS multitined design for basivertebral nerve ablation

- Market Opportunity: Over 5 million people in the United States estimated to have vertebrogenic back pain

- Development Status: Nearing completion (as of 2026)

- Clinical Evidence: First scientific article published in 2024 describing the neurovasis BVNA technique utilizing CT reconstruction for device placement assessment

Stratus® RF Generator

- Platform Technology: Differentiated and patented RF generator to power Stratus RF devices

- Status: Currently being finalized

- Regulatory Note: The Stratus RF Generator and neurovasis technologies have not been submitted, evaluated, or cleared by the FDA as of 2026

Clinical Research and Evidence

COBRA Study

- Study Design: First double-blind, randomized clinical trial comparing Nimbus RF ablation device to traditional RF ablation for sacroiliac joint pain

- Patient Enrollment: First patient enrolled in 2024

- Objective: Quantify effectiveness and duration of pain relief provided by Nimbus bipolar RF ablation

- Institution: Initiated by University of Utah Department of Physical Medicine and Rehabilitation